You are here

Stabilized, Freeze Dried Bacteriophage for use in Austere Environments

Award Information
Agency: Department of Defense
Branch: Defense Health Agency
Contract: W81XWH22P0018
Agency Tracking Number: H21C-003-0006
Amount: $249,909.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: DHA21C-003
Solicitation Number: 21.C
Solicitation Year: 2021
Award Year: 2022
Award Start Date (Proposal Award Date): 2022-03-25
Award End Date (Contract End Date): 2022-10-24
Small Business Information
20 New England Business Center
Andover, MA 01810-1111
United States
DUNS: 073800062
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Emily Gong
 (978) 738-8289
Business Contact
 William Marinelli
Phone: (978) 738-8226
Research Institution
 University of Connecticut
 Tracy Bourassa
438 Whitney Road Ext., Unit 1133
Storrs, CT 06269-1133
United States

 (860) 486-3622
 Domestic Nonprofit Research Organization

Physical Sciences Inc. (PSI), in collaboration with the University of Connecticut (UConn) including Dr. Robin Bogner, with expertise in pharmaceutical freeze drying, and Dr. Carolyn Teschke, with expertise in bacteriophage biology, proposes to develop a formulation and process for lyophilization, or freeze drying, of bacteriophages for improved stability to enable bacteriophage treatments in austere environments. During the Phase I program, a preliminary formulation and freeze drying process will be developed and validated against three bacteriophages (one from each of the three families used in bacteriophage therapies). The Phase I program will demonstrate short-term (one month) stability of bacteriophages stored between -20°C and +45°C. The Phase II program will refine the formulation and freeze drying processes for a wider range of target bacteriophages, demonstrate long-term (six month to one year) stability over a similar range of temperatures, and define the phage delivery method. PSI and UConn will also identify a commercialization and technology transfer partner to license the technology to develop bandages or topical medicines to treat wounds. In the Phase III program, PSI and UConn will develop a commercial product and perform animal models to test the efficacy of the stored bacteriophages to treat infection in wounds.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government